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vision in blind patients and recently reached clinical trials.
Although the ON-bipolar cells, the first retinal interneurons,
make the most attractive targets for optogenetic vision restora-
tion, they have remained inaccessible to human gene therapy
due to the lack of a robust cell-specific promoter. We describe
the design and functional evaluation of 770En_454P(hGRM6),
a humanGRM6 gene-derived, short promoter that drives strong
and highly specific expression in both the rod- and cone-type
ON-bipolar cells of the human retina. Expression also in
cone-type ON-bipolar cells is of importance, since the cone-
dominated macula mediates high-acuity vision and is the pri-
mary target of gene therapies. 770En_454P(hGRM6)-driven
middle-wave opsin expression inON-bipolar cells achieved last-
ing restoration of high visual acuity in the rd1mouse model of
late retinal degeneration. The new promoter enables precise
manipulation of the inner retinal network and paves the way
for clinical application of gene therapies for high-resolution op-
togenetic vision restoration, raising hopes of significantly
improving the life quality of people suffering from blindness.
INTRODUCTION
Optogenetic and gene supplementation therapies to restore vision are
already performed on human patients1 (Table 1). In the sophisticated
neuronal network of the retina,2 targeting therapeutic genes to spe-
cific cell types to achieve precise intervention is often imperative.
While the photoreceptor cells and the retinal pigment epithelium
are targets for gene therapy at early stages of retinal degeneration,
the bipolar cells make promising targets for gene therapy at late stages
of retinal degeneration, when most photoreceptors are lost. The bipo-
lar cells are the first interneurons of the retina that receive direct input
from the photoreceptors. They are divided into ON- and OFF-type
bipolar cells that respond to either light increments or light decre-
ments, respectively, forming the foundation for contrast vision.3 It
was previously shown that optogenetic sensitization of ON-bipolar
cells (OBCs) to light in a photoreceptor-less, blind murine retina
can restore light responsiveness and complex inner retinal signaling,
resulting in diverse receptive-field types in the retinal ganglion cell
population.4,5 Channelrhodopsin-2,5 rhodopsin,6 and chimeric
Opto-mGluR64 have all been expressed in the OBCs of blind rd1
mice to restore functional vision at the retinal, cortical, and behavioralMolecular Therapy: Methods &
This is an open access article under the CC BY-NC-levels. Photoswitchable chemical ligands attached to cysteine-
mutated modified glutamate receptors (LiGluRs) equally restored
visual responses in rd1mice when targeted to the OBCs.7 Besides op-
togenetic approaches, OBCs also present attractive targets for gene
supplementation therapies treating congenital stationary night blind-
ness (CSNB). Most mutations causing CSNB are found in OBC-spe-
cific genes that encode proteins of the mGluR6 signalosome, such as
NYX, GRM6, GPR179, LRIT3, GNB3, and TRPM1.8
Although OBCs were successfully targeted in the mouse retina, they
remained inaccessible to gene therapy in the human retina due to
the lack of molecular tools; in particular, a specific promoter that
can drive strong transgene expression in human OBCs. A reason for
the divergence of promoter performance inmurine and human retinas
is the prominent inter-species functional variability of molecular
tools.9 Further, OBCs are located deep within the retinal tissue,
making them less accessible to viruses. They also appear rather non-
permissive to viral transduction and require highly specialized pro-
moters.9 This becomes evident by the fact that specific targeting of
diverse retinal cell types, but excluding OBCs, was recently achieved
in the primate and human retina using a combinatorial screen of syn-
thetic promoters and novel adeno-associated virus (AAV) capsid var-
iants. OBC-specific expression is important not only for restoring pre-
cise retinal signaling with an optogenetic gene therapy but also for
reducing the risk of toxic and/or inflammatory reactions previously
linked to unspecific protein expression using ubiquitous promoters.10
Due to the species specificity of molecular tools, promoter function
must inevitably be tested in human tissue. A valuable pre-clinical
model to test promoter specificity and efficacy in human tissue is
the post-mortem human retinal explant (HRE). Since promoter spec-
ificity is independent of the viral administration route, a whole-eye
in vivo gene therapy is not required.
The 9.5-kb full-lengthmurineGrm6 promoter is known to exclusively
drive expression in OBCs11 and was successfully used in a transgenicClinical Development Vol. 17 June 2020 ª 2020 The Author(s). 505
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1. Ongoing AAV Gene Replacement and Gene Supplementation Trials in the Retina
ClinicalTrials.gov
identifier Disease Gene
Target
cells Vector Delivery Phase Drug Start
Estimated Date of
completion
NCT03328130 Autosomal recessive RP PDE6B PRs AAV2/5 SR I/II HORA-PDE6B 2017 2022
NCT03374657 Autosomal recessive RP RLBP1 RPEs AAV2/8 SR I/II CPK850 2018 2025
NCT03252847 X-linked RP RPGR PRs AAV2 SR I/II 2017 2020
NCT03116113 X-linked RP RPGR PRs AAV2/8 SR II/III 2017 2020
NCT03316560 X-linked RP RPGR PRs AAV2 SR II/III AGTC-501 2018 2024
NCT01482195 RP MERTK RPEs AAV2 SR I 2011 2023
NCT02556736 Advanced RP ChR2 RGCs AAV2 IVT I/IIa RST-001 2015 2033
NCT03326336 Non-syndromic RP ChrimsonR RGCs AAV2(7m8) IVT I/IIa GS030 2018 2024
NCT03507686 Choroideremia REP1 RPE AAV2 SR II 2017 2020
NCT03496012 Choroideremia REP1 RPE AAV2 SR III 2017 2020
NCT02407678 Choroideremia REP1 RPE AAV2 SR II 2016 2021
NCT02341807 Choroideremia REP1 RPE AAV2 SR I/II 2015 2019
NCT03001310 Achromatopsia CNGB3 PRs AAV2/8 SR I/II 2016 2019
NCT03278873 Achromatopsia CNGB3 PRs AAV SR I/II 2017 2023
NCT02599922 Achromatopsia CNGB3 PRs AAV2 SR I/II 2016 2022
NCT02935517 Achromatopsia CNGA3 PRs AAV2 SR I/II AGTC-402 2017 2021
NCT02610582 Achromatopsia CNGA3 PRs AAV2/8 SR I/II 2017 2021
NCT00516477
Leber congential
amaurosis
RPE65 RPEs AAV2 SR I/II VN 2007 2024
NCT01208389
Leber congential
amaurosis
RPE65 RPEs AAV2 SR I/II VN 2010 2026
NCT00999609
Leber congential
amaurosis
RPE65 RPEs AAV2 SR III VN 2012 2029
NCT02946879
Leber congential
amaurosis
RPE65 RPEs AAV2/5 SR I/II
AAV
OPTIRPE65
2016 2023
NCT00481546
Leber congential
amaurosis
RPE65 RPEs AAV2 SR I 2007 2026
NCT03597399
Leber congential
amaurosis
RPE65 RPEs AAV2 SR
post-
authorization
VN 2019 2029
NCT02416622 X-linked retinoschisis RS1 PRs, BCs AAV2 IVT I/II 2015 2022
NCT02317887 X-linked retinoschisis RS1 PRs, BCs AAV2/8 IVT I/II
RS1 AAV
Vector
2014 2021
NCT02065011 Usher syndrome 1B MY07A PRs LV SR I/II UshStat 2013 2035
NCT01505062 Usher syndrome 1B, RP MY07A PRs LV SR I/II SAR421869 2012 2020
NCT01367444 Stargardt disease ABCA4 PRs LV SR I/II SAR422459 2011 2019
NCT01736592 Stargardt disease ABCA4 PRs LV SR I/II SAR422459 2012 2034
RP, retinitis pigmentosa; AAV, adeno-associated virus; LV, lentivirus; PRs, photoreceptor cells; RGCs, retinal ganglion cells; SR, subretinal injection; RPEs, retinal pigment epithelial
cells; IVT, intravitreal injection; VN, voretigene neparvovecrzyl; BCs, bipolar cells.
Molecular Therapy: Methods & Clinical Developmentmouse line to drive expression in all OBCs of the murine retina.4 For
AAV-based gene therapies, however, short promoter sequences are
required, since the packaging capacity of an AAV is limited (approx-
imately 4.7 kb) and does not accommodate endogenous promoters of
several kilobases in length. In this respect, enhancer promoter combi-
nations derived from Grm6 have proven most successful in driving
transgene expression in murine OBCs. A short 200-bp Grm6
enhancer in combination with a basal viral simian virus 40 (SV40)
promoter (200En-SV40)12 was first used for ectopic channelrhodop-506 Molecular Therapy: Methods & Clinical Development Vol. 17 June 2sin-2 expression in OBCs.5 Introducing a quadruple repetition of the
200-bp Grm6 enhancer preceding the SV40 basal promoter
(4xGRM6-SV40) was later shown to increase transgene expression
in the murine retina.13 Unfortunately, 4xGRM6-SV40 was unable
to drive transgene expression in OBCs of the degenerated rd1 mouse
retina and led to significant off-target expression in ex vivo cultures of
human post-mortem retinas.14 More recently, an entirely murine
Grm6-based short promoter was designed (200En-mGluR500P)
that drives gene expression in the wild-type C57BL/6 mouse retina020
Figure 1. ON-Bipolar Cells as Therapeutic Targets in
Retinal Degeneration
(A) Schematic of a healthy retina on the left and a degen-
erated retina lacking photoreceptors on the right. PR,
photoreceptor; HC, horizontal cell; OBC, ON-bipolar cell;
OFFBC, OFF-bipolar cell; AC, amacrine cell; GC, ganglion
cell. In retinal degeneration, the most distally remaining
cells of the visual pathway are the OBCs, which can be
engineered into “replacement photoreceptors” by an op-
togenetic gene therapy. (B) ThemGluR6 signalosome in the
dendritic tips of OBCs and proteins therein that are affected
by loss-of-function mutations—indicated with stars—in
congenital stationary night blindness. OBC-targeted gene supplementation therapies can restore function. mGluR6 is a metabotropic glutamate receptor that activates
trimeric Gao/Gb3/Gy13 gating the cation channel TRPM1. LRIT3 is required for proper localization of TRPM1, and GPR179 and NYX are scaffolding proteins.
www.moleculartherapy.orgwith high OBC specificity.15 However, expression in OBCs of the de-
generated retina and in human tissue was not investigated, and trans-
gene expression in the murine retina was almost exclusively restricted
to the rod-type OBCs (rOBCs). Since high-resolution macular vision
is mediated by cones and cone-type OBCs (cOBCs) of the midget
pathway in a human, it is imperative for a gene therapy targeting
the OBC population to achieve robust expression in the cOBCs.
Here, we introduce a novel synthetic promoter derived from the hu-
man GRM6 gene, consisting of a core promoter element and an
enhancer element, which drives transgene expression in OBCs in a
robust and highly specific (approximately 90%) manner when deliv-
ered by an AAV gene therapy, not only in late degenerated murine ret-
inas but particularly also in human ex vivo retinas. Proof of function-
ality in the human retina is important due to the known variability of
cell-type targeting by synthetic promoters across species.9 A further
advantage of the novel 770En_454P(hGRM6) promoter is its ability
to drive strong expression in cOBCs of the human macula, with no
selectivity for rOBCs over cOBCs; this is not only important because
the cone-dominated fovea mediates high-acuity vision, but also
because current retinal gene therapies (Table 1) almost exclusively
target the macular region, which is most permissive to AAV transduc-
tion in humans and primates.16 Further advantages of the
770En_454P(hGRM6) promoter are that it mediates low off-target
gene expression in other retinal cell types of the human retina and
that it complies in size (1.2 kb) with other promoters used in AAV
gene therapies.
The 770En_454P(hGRM6) promoter paves the way toward OBC-tar-
geted gene therapies, including high-resolution optogenetic vision
restoration and treatment of CSNB, thereby bringing hope to millions
of people suffering from photoreceptor degeneration. Giving access to
OBCs for genetic manipulations makes 770En_454P(hGRM6) also a
welcome tool to unravel inner retinal signaling across species, across
health and disease, and across different approaches of prosthetic
restoration.
RESULTS
The OBCs make promising targets for gene therapy, either to replace
malfunctioning genes causative of congenital stationary night blind-
ness or to restore vision by an optogenetic supplementation therapyMoleculwhen photoreceptors are lost (Figure 1). Bipolar cells are the first in-
terneurons of the retinal neuronal network and remain relatively well
preserved in advanced retinal degeneration,17 which allows optoge-
netic restoration of sophisticated visual signaling4,6 (Figure 1A). Pre-
clinical endeavors are underway that supply functional versions of
mutated genes to the OBCs to restore the mGluR6 signaling pathway
in CSNB patients8 (Figure 1B) and, with that, OBC function and
vision.18 The mGluR6 receptor is exclusively expressed in the
OBCs;4,11 therefore, the Grm6 gene makes a valuable target for pro-
moter design. It was shown that the murine Grm6 enhancer in com-
bination with the SV40 viral promoter is able to drive OBC-enriched
expression of exogenous transgenes in the murine retina.13
Changes in Grm6 Transcription during Retinal Degeneration
Since we recently showed that expression from the 4xGRM6-SV40
promoter is severely downregulated in 8-week-old rd1 (C3H/
HeOu) mice with retinal degeneration, even when the gene therapy
was performed early at postnatal day 24 (P24),14 we quantified
Grm6 transcription in the retinas of rd1 mice of up to 10 months of
age by quantitative real-time PCR to ascertain whether Grm6 expres-
sion was downregulated during the degenerative process. Thereby, we
assumed that promoters active in the aggressive rd1 photoreceptor
degeneration mouse model are likely to be active in less severe degen-
erative models, as we have shown for the 4xGRM6-SV40 promoter,
which is still active in the slower rd10 (B6.CXB1-Pde6brd10) photo-
receptor degeneration mouse line—but not in the rd1 model—
although with considerable off-target expression.14
We quantified Grm6 transcription at P14, P21, P28, P54, and P318 in
homogenized entire rd1 retinas and determined Grm6 transcription
levels relative to transcription levels in wild-type C57BL/6 mouse ret-
inas (n = 4, P54; Figure 2). Ribosomal protein L8 (Rpl8) was used as a
reference gene, and Rho was used as marker for progressing photore-
ceptor degeneration. At P21, the relative Rho expression falls to 0.8%
of its expression in adult C57BL/6 mice (Figure S1), consistent with
severe rod photoreceptor loss. To compensate for the remaining pho-
toreceptors in the early stages of degeneration that would bias toward
an underestimation of Grm6 levels compared to the levels in late
stages, we normalized the measured Grm6 transcription values
against the remaining Rho transcription levels (Equation 3, in Mate-
rials and Methods). Figure 2 shows that the largest reduction in Grm6ar Therapy: Methods & Clinical Development Vol. 17 June 2020 507
Figure 2. Grm6 Transcription throughout Degeneration in the rd1 Mouse
Model
Grm6 transcription quantified by quantitative real-time PCR in whole rd1 retinas (n =
6 at each time point) relative to Grm6 transcripts in wild-type C57BL/6 mouse ret-
inas (n = 4). Measured values (C); rod degeneration corrected values (>). Grm6
transcription starts decreasing beyond P21, following a power function, R2 =
0.9866, and stabilizing around 40%of initialGrm6 transcription in late degeneration.
ERG, electroretinogram. Data are represented as mean ± SD of biological repli-
cates.
Molecular Therapy: Methods & Clinical Developmenttranscription (33.3%) takes place between P21 and P28, following
the peak rod degeneration at P12–P14. Subsequently,Grm6 transcript
levels in the rd1 retina stabilized at around 40% of the wild-type
C57BL/6 level. This suggests that the silencing of 4xGRM6-SV40-
driven expression in OBCs of the rd1 mouse retina14 was unlikely
to be due to the Grm6 enhancer. Having confirmed sustained Grm6
transcription throughout the entire process of retinal degeneration,
we chose theGRM6 genome sequence as a template for synthetic pro-
moter design.
Design of Short Human GRM6-Based Promoters
To optimally comply with the human transcription machinery, we
based the promoter design on the human GRM6 gene. To find poten-
tial regulatory genome sequences, we identified inter-species
conserved DNA, active chromatin regions (DNase I hypersensitivity
clusters or H3K27 acetylation), and potential transcription factor
(TF) binding sites. The Gene Transcription Regulation Database
(GTRD)19,20 was used to retrieve chromatin immunoprecipitation
DNA-sequencing (ChIP-seq) peaks, which provide experimentally
verified TF binding sites.
To define the proximal promoter region, we focused on the 1,000 bp
immediately 50 of the translation start site (TLSS, defined as position
0; Figure 3A). When aligning the human and mouse sequences, we
identified a 167-bp conserved sequence (425 to 259; Figure 3A,
striped region). We chose the first promoter variant, 566P (691 to
126), to contain this 167-bp conserved sequence, the 30 transcrip-
tion start site (TSS; 179), and the 50 H3K27Ac Mark signal peak
(656 to405), as well as the potential binding site for the activating
TF ERG. The second selected promoter variant, 454P (453 to +1)
also contains the full conserved 167-bp sequence but extends a further508 Molecular Therapy: Methods & Clinical Development Vol. 17 June 230 compared to 566P, reaching the translation start site (TLSS) and
additionally containing the potential binding sites for the TFs
MYC, POU5F1, and TCF7L1.
To select potential enhancer sequences, we focused on the human
GRM6 region around the sequence syntenic to the murine 200En
Grm6 enhancer previously identified by Kim and colleagues.12 We
identified a 310-bp-long sequence conserved between mouse and hu-
man genomes (13,819 to13,510) and extending beyond themurine
200En Grm6 enhancer in both 30 and 50 directions (Figure 3B, striped
section). We selected two enhancer variants, 407En and 770En. The
short 407En enhancer (13,873 to 13,467) contains the entire iden-
tified 310-bp conserved sequence. The longer 770En enhancer addi-
tionally contains all regulatory regions of interest in the 50 direction,
such as potential binding sites for the TFs DACH1, FLI1, and CTCF,
as well as a DNase I hypersensitivity cluster (13,990 to 13,816).
Evaluation of Promoters in the Human Retina
The human post-mortem retinal explant presents a valuable pre-clin-
ical model for promoter testing; not only is it known that promoter
activity and specificity vary largely among species,9 but evaluation
of promoter specificity also does not require a whole-eye in vivo
gene therapy, since it is independent of the viral administration route.
For transduction of post-mortem human retinas, we cloned three
GRM6 enhancer/proximal promoter combinations (Table 2) upstream
of the mCitrine reporter gene.We packaged expression constructs into
the AAV2(7m8)21 viral capsid, which is already being used for intravi-
treal injections into human eyes (ClinicalTrials.gov: NCT03326336).
We used self-complementary (sc) AAV capsids that mediate faster
gene expression (within approximately 1 week) compared to single-
stranded (ss) AAVs (approximately 4–5 weeks), which is advantageous
when working with ex vivo retinal cultures of limited longevity.
6  108–1.5  1010 vgs (vector genomes) were added to the ganglion
cell side of cultured HREs at day 1. Explants were frozen and immu-
nolabeled at day 8 of culture when mCitrine expression became
detectable by eye (Figure S2). Cryosections were co-labeled with the
nuclear stain DAPI to distinguish cell layers and antibodies against
mCitrine (transgene) and Gao (OBC marker) to derive the identity
of expressing [mCitrine+] cells. Photoreceptors are located in the
outer nuclear layer (ONL), OBCs label positive for Gao and are
located in the inner nuclear layer (INL), and ganglion cells are located
in the ganglion cell layer (GCL) (Figures 4A and 4C). All three pro-
moters—as opposed to highly unspecific transgene expression driven
by 4xGRM6-SV40 (Figure S3)—showed high specificity for OBCs:
407En_454P(hGRM6) drove mCitrine expression in 83% ± 4% of
OBCs, 407En_566P(hGRM6) drove expression in 75% ± 21% of
OBCs, and 770En_454P(hGRM6) drove expression in 88% ± 13%
of OBCs. To quantify promoter strength, we measured cytoplasmic
Alexa 488 (secondary antibody for mCitrine) fluorescence in trans-
duced OBC cell bodies (for details, refer to Materials and Methods).
As evident from Figure 4B, promoters 770En_454P(hGRM6) (5.3 ±
1.3; n = 4; p = 0.002) and 407En_454P(hGRM6) (4.9 ± 0.2; n = 3;020
www.moleculartherapy.orgp = 0.005) produced higher fluorescence values (FVs) than
407En_566P(hGRM6) (1.6 ± 0.2; n = 3), indicative of their superior
performance in driving transgene expression.cOBC preferenceð%Þ = 100 x expression efficacyðcOBCÞ
expression efficacyðcOBCÞ+ expression efficacyðrOBCÞ: (Equation 2)For all subsequent experiments, we therefore used promoters with the
promoter element 454P, which produced more efficient and stronger
mCitrine expression.
Significantly Enhanced cOBC Preference in HREs
Currently, AAV gene therapies almost exclusively target the macula,
the central area of the retina comprising the fovea centralis, whichme-
diates high-acuity vision.22 The ONL of the human fovea exclusively
contains cones, which connect to cone bipolar cells in the inner retina
forming the midget pathway underlying high-acuity vision. Fovea-
targeted retinal gene therapy, therefore, demands a promoter that
effectively drives expression in cOBCs.
To quantify selective expression in cOBCs, we performed triple la-
beling of human retinal cryosections with antibodies against the re-
porter protein mCitrine, Gao or Gy13 (ubiquitous OBC markers),
and the rOBC cell-specific antibody protein kinase C alpha
(PKCa) to distinguish rOBCs [PKCa+ and Gao+/Gy13+] and
cOBCs [PKCa and Gao+/Gy13+]. Figure 4C shows that
770En_454P(hGRM6) drives expression in both rOBCs and cOBCs.
We counted mCitrine-expressing cOBCs as a fraction of all re-
porter-expressing OBCs and found that 770En_454P(hGRM6)
drove expression in cOBCs at a higher ratio (22.3% ± 8.6%)
compared to 407En_454P(hGRM6) (13.5% ± 1%). Since both pro-
moters are active in rOBCs and cOBCs, the resulting expression ra-
tio will always be influenced by the cOBC-to-rOBC ratio present in
the transduced tissue, which varies in different retinal regions; the
occurrence of cOBCs outside of the macula is low compared to
the abundance of rOBCs.23 To get a measure of the preference of
a promoter for cOBCs, which is independent of the cOBC-to-
rOBC ratio, we first calculated the expression efficacies for rOBCs
and cOBCs separately (Equation 1).Expression efficacy ðrOBCsÞ = expressing rOBCs ½P
all rOBCs ½PKC
Expression efficacyðcOBCsÞ = expressing cOBCs ½P
all cOBCs ½PKC
MoleculTo get a measure for the absolute cOBC preference, independent of
the retinal region, we then normalized cone-type expression efficacy
to the local abundance of cones (Equation 2).The cOBC preference of 770En_454P(hGRM6) was 48.2% ± 5.9%,
indicating a virtually equal preference of the promoter for cOBCs
and rOBCs. The cOBC preference of 770En_454P(hGRM6) was
significantly higher (95% confidence interval [CI95%] of difference =
5.23–18.26, p = 0.004) than that of 407En_454P(hGRM6) (36.4% ±
2.3%; Figure 4D). To corroborate the excellent performance of
770En_454P(hGRM6) in cOBCs, we also cultured and transduced
explants of human maculas where cOBCs largely predominate. As
exemplified in Figure 5, 770En_454P(hGRM6) drove gene expres-
sion in macular cOBCs with high efficiency.
Transgene Expression Driven by Promoter 770En_454P(hGRM6)
Is Independent of the Viral Capsid, Widespread, and Highly OBC
Specific
To get a measure for the spread and distribution of expression pro-
duced by 770En_454P(hGRM6), we labeled transduced human
retinal flat mounts with antibodies against mCitrine and Gao and
determined the average amount of expressing OBCs on a large scale
(Figure 6). We observed uniform mCitrine expression, targeting up
to 82% of OBCs throughout the area of transduction (Figures 6A–
6F). In particular, the efficacy of OBC-targeted mCitrine expression
remained constant throughout the INL, regardless of depth (Figures
6C–6E), corroborating 770En_454P(hGRM6)’s equal preference for
cOBCs (localized within the inner INL) and rOBCs (localized within
the outer INL). To assess whether OBC specificity was influenced by
the viral capsid, we compared mCitrine expression profiles produced
by 770En_454P(hGRM6) side-by-side when packaged into
scAAV2(7m8) and scAAV2(Y252,272,444,500,700,730F). The
mutated variant AAV2(Y252,272,444,500,700,730F) was designed
based on the findings of Petrs-Silva and colleagues24 and was previ-
ously shown to transduce OBCs after intravitreal delivery in mice.4
As shown in Figure 6G, the 770En_454P(hGRM6)-driven mCitrineKCað+ Þ;Gaoð+ Þ;mCitrine+ 
að+ Þ;Gaoð+ Þ in region
KCað  Þ;Gaoð+ Þ;mCitrine+ 
að  Þ;Gaoð+ Þ in region : (Equation 1)
ar Therapy: Methods & Clinical Development Vol. 17 June 2020 509
Figure 3. Design of Short Promoters based on Human GRM6
(A) Genomic region upstream of the translation start site (TLSS) showing the two selected proximal promoter variants, 566P and 454P. (B) Distal genomic region showing the
two selected enhancer elements, 407En and 770En. Shaded regions indicate high sequence conservation between the murine and human genomes. Sequence locations
are given relative to the TLSS. Markers for regulatory elements: DNase I hypersensitivity clusters, H3K27 acetylation marks, sequence conservation across 100 vertebrates
(100 Vert. Cons) and ChIP-Seq peaks. TSS, transcription start site. Images were downloaded from the University of California, Santa Cruz (UCSC), Genome Browser at
https://genome.ucsc.edu/ and modified.
Molecular Therapy: Methods & Clinical Developmentexpression profile was identical for both capsids, targeting equal levels
of OBCs (scAAV2(7m8): 88.1% ± 13.1%, n = 3; scAAV2
(Y252,272,444,500,700,730F): 89.7% ± 3.5%; n = 3). Consequently,
the high OBC specificity produced by 770En_454P(hGRM6) is a
property of the promoter and independent of the AAV capsid.
Significant transgene expression in cells other than OBCs could lead
to cytotoxicity and inflammatory reactions as well as to corrupt
signaling in an optogenetic approach. Therefore, we quantified and
compared OBC-specific and off-target transgene expression by
measuring Alexa 488 fluorescence of the immunolabeled mCitrine re-
porter protein throughout the retina. Figure 6H shows that the
normalized FVs in OBCs are significantly higher compared to those
in other cells, which include ganglion cells, amacrine cells, photore-510 Molecular Therapy: Methods & Clinical Development Vol. 17 June 2ceptors, and OFF-type bipolar cells. Further, the equivalent FVs of
rOBCs (5.4 ± 2.2) and cOBCs (5.2 ± 1.7) again confirmed equal func-
tionality of 770En_454P(hGRM6) in both OBC types. In combination
with the low off-target transduction rate (Figure 6G), we consider
functional interference or induction of cytotoxic/inflammatory re-
sponses arising from off-target protein expression to be rather un-
likely. To understand whether the ratio of off-target versus on-target
expression is dependent on the viral dose applied, we correlated in
different locations of the retinal explants OBC expression specificity
and expression efficacy, the latter being directly dependent on the
applied AAV dose (Figure S4). The correlation of specificity and effi-
cacy was not significant (p = 0.18), from which we conclude that the
OBC specificity of 770En_454P(hGRM6)-driven expression is inde-
pendent of AAV dose.020
Table 2. Selected Enhancer/Promoter Combinations
Name GenBank identification Length
407En_454P(hGRM6) MT_212169 867 bp
407En_566P(hGRM6) MT_212170 978 bp
770En_454P(hGRM6) MT_212168 1243 bp
www.moleculartherapy.orgThe combination of high OBC specificity and efficacy of expression
driven by 770En_454P(hGRM6) allows for cell-type-specific inter-
vention, maximizing functional outcome and reducing undesired
side effects.
Optogenetic Vision Restoration with 770En_454P(hGRM6)-
Driven OBC-Targeted Middle-Wave Opsin Expression in Fully
Degenerated rd1 Mouse Retinas
The tissue’s accessibility to treatment is important for a retinal gene
therapy. This can be challenging in a degenerative process accompa-
nied by anatomical, functional, and transcriptional changes within
the tissue.25 HREs are not a degenerated tissue; therefore, we used
the harsh photoreceptor degeneration rd1 mouse model to test
770En_454P(hGRM6)’s performance in the degenerated retina. The
4xGRM6-SV40 promoter,13 for example, was no longer functional
in the OBCs of rd1 mice when injected at 3.5 weeks of age and eval-
uated at 7.5 weeks of age.14 To challenge the performance of
770En_454P(hGRM6), we performed an optogenetic gene therapy
in late degenerated, 22-week-old rd1mice (n = 8). For this, we cloned
an expression cassette in which promoter 770En_454P(hGRM6)
drives the expression of murine medium-wave-sensitive cone opsin
1 (Opn1mw) and a red fluorescent protein (TurboFP635). We fused
Opn1mw C-terminally with the entire C terminus of the OBC-specific
mGluR6 receptor to achieve correct subcellular localization within
the mGluR6 signalosome of the bipolar cell. We further added
C-terminally a Golgi export signal (TS)26 and the rhodopsin mem-
brane trafficking sequence (TETSQVAPA) to improve membrane
targeting. 770En_454P(hGRM6)-Opn1mw-CTmGluR6-TS-1D4-
IRES2-TurboFP635 (Figure S5) was packaged into ssAAV2(7m8),
and 1 1011 vgs were bilaterally and intravitreally injected. To ascer-
tain functionalOpn1mw expression, we quantified the visual acuity by
detecting the optomotor response (OMR).27 Briefly, the OMR of a
mouse is a compensatory head movement reflex that serves the stabi-
lization of a globally shifting visual image on the retina. By presenting
to a mouse a laterally moving vertical black-and-white striped
pattern, the highest spatial frequency that still elicits the OMR can
be determined by stepwise increasing the spatial frequency of the
pattern until the OMR is lost. The detection threshold can then be
translated into the visual acuity of vision. We measured the OMR
of the treated mice repeatedly between 28 and 38 weeks of age
(n = 3). The average visual acuity of the treated mice was 0.28 ±
0.02 cycles per degree (cpd), which was significantly improved
(CI95% of difference = 0.087–0.237, p = 0.0001) compared to that of
non-injected rd1 littermates (0.12 ± 0.03 cpd; n = 5), reaching 65%
of the values of seeing C57BL/6-positive controls (0.43 ± 0.05 cpd;
n = 10; CI95% of difference = 0.081–0.217, p = 0.0001) (Figure 7A).MoleculImportantly, restored visual acuity did not decrease over the 10-
week test period (Figure S6), which is indicative of a halt or slowing
down of retinal degeneration through optogenetic re-activation of in-
ner retinal signaling. Mice were subsequently euthanized to visualize
the retinal TurboFP635 expression pattern. Remarkably, transgene
expression was found as virtually pan-retinal even in these very late
degenerated retinas (rd1, 41 weeks of age: Figure 7B). Cryosections
from additional treated rd1 mice (n = 5) sacrificed at 26 weeks of
age revealed that 770En_454P(hGRM6), in contrast to 4xGRM6-
SV40, is able to drive Opn1mw expression also in OBCs of the degen-
erated retina with good expression efficacy (57.1% ± 4.3%; Figure 7C)
and OBC specificity (59.1% ± 10%; Figure 7D). For comparison,
expression specificity in wild-type C57BL/6 mice is higher (70.6% ±
5%; Figure S7), probably a consequence of transcriptomic changes
during the process of degeneration.14 Nonetheless, the good restora-
tion of visual acuity in rd1 mice confirms that the OBC specificity of
770En_454P(hGRM6) in rd1mice is still high enough to separate the
retinal ON and OFF channels underlying contrast detection.
The extent to which degeneration will affect 770En_454P(hGRM6)
promoter specificity in humans will need to be investigated, but wide-
spread, cell-specific, functional, and stable therapeutic transgene
expression in a degenerated retina well beyond any remaining retinal
responsiveness or visual behavior (>24 weeks in rd1 mice)4,28 is, un-
doubtedly, a fundamental prerequisite for an effective gene therapy.
DISCUSSION
Retinal diseases are almost exclusively cell-type specific, and expres-
sion of a therapeutic gene in off- target cells was reported to enhance
cytotoxic effects.10 The challenge for gene therapy is, therefore, to
achieve cell-type-specific transgene expression at functional levels.
Such cell-type-specific treatment is, in particular, indispensable
when optogenetic therapy is aimed at bipolar cells to restore complex
and finely balanced inner retinal signaling between distinct retinal cell
types. A further challenge is to achieve robust and specific transgene
expression in degenerated tissue, since cellular transcriptomes often
change in degeneration.14 OBCs have proven particularly challenging
target cells. Not only do they lie deep within the retina, making them
less accessible to viruses, but they also appear rather non-permissive
to viral transduction and require highly specialized promoters.9
Although murine OBCs were targeted with Grm6-derived promoters,
albeit with varying specificity,13,15,29 this success was not translated
into human tissue (Figure S3) or late degenerated retinas.14 The novel
770En_454P(hGRM6) promoter presented here paves the way for
OBC-targeted human gene therapy. 770En_454P(hGRM6) not only
targets a high percentage of OBCs throughout the human retina
but also does this with a very high specificity for OBCs of approxi-
mately 90%. 770En_454P(hGRM6) also fulfills other requirements
that render it well suited for a human retinal gene therapy: (1) it is suf-
ficiently short (1,243 bp) to fit, together with a therapeutic transgene
(i.e., an optogene), into an AAV capsid; (2) it is derived from the hu-
man genome and, therefore, optimally controlled by the human tran-
scription machinery; (3) it possesses high functionality in the cOBCs,ar Therapy: Methods & Clinical Development Vol. 17 June 2020 511
Figure 4. Functionality and ON-Bipolar Cell-Type Preference of Novel Synthetic Promoters in Post-mortem HREs
(A) Vertical cryosections through the mid-periphery of the human retina transduced with 770En_454P(hGRM6)-mCitrine. The nuclear stain DAPI differentiates the cell layers,
the outer nuclear layer (ONL), the inner nuclear layer (INL), and the ganglion cell layer (GCL). In this example, 83% of ON-bipolar cells (OBCs) express the reporter mCitrine.
Scale bar, 80 mm. (B) Quantification of the promoter strengths bymeasuring the fluorescence of immunolabeled mCitrine in expressing OBCs. Statistical analysis by one-way
ANOVA with post hoc Tukey HSD test; **p < 0.01; n.s., p > 0.05, not significant. (C) As in (A), but triple staining allowing distinction between rOBCs and cOBCs. In this
example, 66% of OBCs express mCitrine. The magnified inserts show the differential labeling of rOBCs (Gao+, PKCa+) and cOBCs (Gao+, PKCa). Expression efficacies,
after Equation 1, and bipolar cell type preferences, after Equation 2, have been calculated for the given example. Scale bar, 50 mm. (D) Quantification of the overall cOBC
preference of promoters 770En_454P(hGRM6) (n = 6) and 407En_454P(hGRM6) (n = 3). Statistical analysis byWelch’s t test; **p < 0.01. Data are represented asmean ± SD
of biological replicates.
Molecular Therapy: Methods & Clinical Developmentenabling macular OBC-targeted gene therapy for restoration of high-
acuity vision; and (4) it drives expression at therapeutic levels also in
degenerated tissue, leading to functional restoration. This was shown
by the good restoration of the OMR in treated rd1 mice with retinal
degeneration, despite a significantly higher inner retinal off-target
expression (27%) compared to HREs (5%). Reasons for the difference
are potentially the human origin of the 770En_454P(hGRM6) pro-
moter as well as the degenerative process, which is known to alter
cellular transcriptomes;14 corroborating the latter, we found that
the inner retinal off-target expression of 770En_454P(hGRM6)-
driven optogene expression in wild-type C57BL/6mice is significantly
lower (12.9% ± 4.8%; Figure S6) than in rd1mice (26.8% ± 7.2%, p =
0.0153; Figure 7D). Nonetheless, despite off-target expression of me-
dium-wave cone opsin in cells other than OBCs, contrast sensitivity
triggering the OMR was clearly restored, confirming successful
re-establishment of the ON and OFF pathways emerging at the level
of the bipolar cells.30 Since OBC specificity of 770En_454P(hGRM6)-
driven expression in HREs is very high (approximately 90%), it is
expected that visual acuity will be reasonably well restored also in
future human patients. Of course, off-target expression is relevant
not only for optogenetic restoration but also for gene delivery in gen-512 Molecular Therapy: Methods & Clinical Development Vol. 17 June 2eral, since significant transgene expression in cells other than OBCs
could lead to cytotoxicity and inflammatory responses;31 however,
the number of expressing off-target cells is small compared to that
of expressing OBCs, and transgene expression levels in off-target
cells are significantly lower than those in OBCs (Figures 6G and
6H), rendering cytotoxic effects caused by off-target expression
improbable.
AAV-mediated optogenetic gene therapy is, currently, the most
promising approach to treat end-stage photoreceptor degenerative
diseases of the retina independent of the underlying pathology,
such as, for example, hereditary retinitis pigmentosa or geographic at-
rophy in late dry age-related macular degeneration. The two ongoing
clinical trials by Allergan (ClinicalTrials.gov: NCT02556736) and
GenSight Biologics (ClinicalTrials.gov: NCT03326336) target chan-
nelrhodopsins (ChR232 and ChrimsonR,33 respectively) to the retinal
ganglion cells. This will potentially restore luminance detection but
with low visual acuity, since the diverse ganglion cell types (ON,
OFF, transient, and sustained) will be engineered into one uniform
response type, a sustained ON ganglion cell that starts firing action
potentials when the light is turned on and stops signaling when light020
Figure 5. Promoter 770En_454P(hGRM6) Effectively
Targets cOBCs of the Human Macula
(A) Terminology of macular areas with location of image
acquisition indicated in (B)–(D). (B and C) Foveal (B) and
para-foveal (C) sections. Scale bars, 50 mm. (D) Foveal flat
mount. Scale bar, 200 mm. (E) Magnification of area indi-
cated in (D). Scale bar, 50 mm. Local ON-bipolar cell
expression efficacies are given in percentages. INL, inner
nuclear layer.
www.moleculartherapy.orgis turned off. Use of 770En_454P(hGRM6), in contrast, enables opto-
genetic activation of OBCs and, with that, restoration of inner retinal
signaling between bipolar, amacrine, and ganglion cells, which under-
lies high-level image formation, including contrast signaling and the
detection of movement. Channelrhodopsins as therapeutic optoge-
netic tools potentially bear some disadvantages as well: they are of
microbial origin, which may elicit an immunogenic response in a
patient, and they require very high-activation light intensities,
enhancing the risk of tissue phototoxicity in the treatment34 andmak-
ing the use of image processors necessary. To overcome the afore-
mentioned potential drawbacks, research has started targeting
OBCs with more refined, next-generation optogenetic tools based
on human opsins, such as Opto-mGluR64 and rhodopsin.6 Being
G-protein-coupled receptors, these tools profit from an approxi-
mately 1,000-fold signal amplification mediated by the coupled intra-
cellular G-protein cascade and endowOBCs with environmental light
sensitivity.4 Here, we expanded the set of OBC-targeted optogenetic
strategies by implementing Opn1mw as a tool to render OBCs light
sensitive. Opn1mw is expressed in green-light-sensitive cones,
where it naturally couples to transducin, a Gi-type protein. Due to
its Gi-type preference, Opn1mw has the ability to couple into the
endogenous Gio-pathway of OBCs. We could demonstrate thatMolecular Therapy: Methods770En_454P(hGRM6)-driven, OBC-targeted
Opn1mw expression restores the OMR at envi-
ronmental illumination intensities (1013 photons
cm2 s1) in otherwise blind rd1 mice. Notably,
the restored discrimination of 0.28 cpd is sub-
stantially improved compared to values previ-
ously reported (0.056 cpd) for rd1 mice treated
by unspecific, hSyn-promoter-driven retinal
Opn1mw expression.35 This corroborates the
importance of OBC-specific promoters for the
restoration of high-acuity-pattern vision. It is
also of note that we treated rd1 mice at particu-
larly late stages of degeneration (22 weeks of
age), when neither retinal responsiveness nor vi-
sual behavior remained,4,28 confirming the high
functionality of promoter 770En_454P(hGRM6).
Further, it was remarkable that the quality
of restored visual acuity persisted robustly
throughout the testing period and up to
10 months of age, indicative of a stabilization of
inner retinal degeneration possibly due to there-activation of retinal light signaling. All the aforementioned data
are fundamental for a durable treatment of a human patient where
the diagnosis of vision loss typically takes place during the late stages
of degeneration.
Besides optogenetic therapies, OBC-targeted gene supplementation
therapies with the potential of treating CSNB will also profit from
770En_454P(hGRM6). Most forms of CSNB are caused by muta-
tions within OBC-expressed genes such as NYX, GRM6, TRPM1,
GPR179, GNB3, and LRIT3, which encode proteins involved in
the OBC-signaling cascade8 (Figure 1B). Preclinical endeavors are
underway that supply a functional version of the mutated gene to
the OBCs to restore the mGluR6 signaling pathway and, with
that, OBC function and vision.18 In terms of translation into the
clinics and testing in human subjects, we see no major challenge
for 770En_454P(hGRM6). Regarding safety, 770En_454P(hGRM6)
consists of entirely human DNA elements. In terms of efficacy,
mCitrine expression was visible by eye already 7 days post-transduc-
tion, and sufficient OPN1mw was expressed in the rd1 mouse retina
to restore a solid OMR; however, the efficacy of expressing larger,
more complicated proteins, such as membrane proteins—in partic-
ular, optogenetic proteins—in the human retina remains to be& Clinical Development Vol. 17 June 2020 513
Figure 6. Capsid-Independent and Widespread ON-Bipolar Cell-Specific Expression Driven by Promoter 770En_454P(hGRM6) in HREs
(A) Flat mount transduced with scAAV2(7m8)-770En_454P(hGRM6)-mCitrine, with the application site indicated with blue arrowheads pointing toward pipette marks.
mCitrine indicates that the drop of viral solution remained locally at the application site and, consequently, accessed the inner nuclear layer (INL) predominantly through the
inner limiting membrane. Red arrowhead indicates blood vessel. Scale bar, 500 mm. (B–F) The ON-bipolar cell (OBC) expression efficacy, given in percentages, remained
approximately constant throughout the explant (B–E), throughout the inner edge (C), middle (D) and outer edge (E) of the INL, and in explants from different donors (A–E
versus F). IPL, inner plexiform layer; OPL, outer plexiform layer. Scale bars: 100 mm in (B) and 50 mm in (C)–(F). Staining in (B)–(F) was done with anti-Gao and anti-mCitrine. (G)
Transduction fingerprint shown to be independent of the viral capsid used. AAV2(7m8) (n = 3) and AAV2(Y252,272,444,500,700,730F) (n = 3) produced virtually identical
expression profiles with a high OBC specificity of88%. Off-target INL includes OFF-bipolar cells and amacrine cells. GCL, ganglion cell layer; ONL, outer nuclear layer. (H)
Somatic fluorescence intensities produced by 770En_454P(hGRM6) quantified in immunolabeled cryosections (n = 3). The fluorescence intensities in rOBCs and cOBCs
were significantly higher than the intensities in off-target populations. Statistical analysis by one-way ANOVA with post hoc Tukey HSD test: *p < 0.05; **p < 0.01. Data are
represented as mean ± SD of biological replicates.
Molecular Therapy: Methods & Clinical Developmenttested. In terms of manufacturing, which mainly concerns the AAV
capsid and not the transgene, we foresee no issues for
770En_454P(hGRM6), since it complies in size with other pro-
moters used in ssAAV gene therapy.
The center of the human retina (fovea centralis), which mediates
high-acuity vision, and the surrounding central retina, the macula,
are understandably the primary focus of current retinal gene ther-
apies.22 Promoter 770En_454P(hGRM6) empowers OBC-targeted
macular gene therapies with the promise to restore high-quality
vision. In age-related macular degeneration, Stargardt disease,
and cone-rod dystrophies, the macular cones are primarily
affected.36 The macula, however, is also affected in later stages of
rod-cone dystrophies, such as hereditary retinitis pigmentosa.37
Subretinal injections typically place AAVs close to the central
retina. Intravitreal injections currently also only lead to transgene
expression within the macula of primates and probably also hu-514 Molecular Therapy: Methods & Clinical Development Vol. 17 June 2mans.38,39 The reason is 2-fold: first, only in the macular region
is the inner limiting membrane barrier thin enough to allow viral
particles to pass. Second, the bipolar and ganglion cells connecting
to the foveal cones are laterally pushed aside from the fovea,
rendering them directly accessible from the vitreous.16,40 Of
course, endeavors are being made to achieve pan-retinal transduc-
tion, such as multifocal subretinal injections, inner limiting mem-
brane peeling before intravitreal injection,38 and AVV engineering
for improved penetration of the inner limiting membrane.21
Despite the unarguable importance of the macula as a target for
gene therapy, transduction of macular OBCs has, however, not
yet been achieved. This is because the macula is dominated by
the cOBCs, which remained, until the development of
770En_454P(hGRM6), inaccessible to transgene expression. The
reason for this may be that cOBCs require particularly specialized
promoters. Which elements of 770En_454P(hGRM6) then could
convey the high functionality in the cOBCs? cOBC functionality020
Figure 7. Promoter 770En_454P(hGRM6) Drives
Stable, Functional, and Widespread Opn1mw
Expression in Late Degenerated rd1 Mice
(A) AAV2(7m8)-770En_454P(hGRM6)-Opn1mw-IRES2-
TurboFP635-injected rd1mice were tested for visual acuity
determined by the optomotor reflex between 28 and
38 weeks of age (n = 3) and compared to their untreated
littermates (n = 5). Optogenetically treated mice showed
significant restoration of visual acuity with a restoration of
65% of the visual acuity of wild-type mice (C57BL/6; n =
10). (B and C) Retinas of the treated animals were im-
munohistochemically evaluated for their expression pro-
files, as indicated in the whole mounts of (B) at 41 weeks of
age and (C) at 26 weeks of age. Scale bars: 1,000 mm in (B)
and 50 mm in (C). (D) 770En_454P(hGRM6) had a signifi-
cant specificity for ON-bipolar cells (OBCs) also in late de-
generated tissue at 26 weeks of age. INL, inner nuclear
layer; GCL, ganglion cell layer. Statistical analysis by one-
way ANOVA with post hoc Tukey HSD test: *p < 0.05;
***p < 0.001. Data are represented as mean ± SD of bio-
logical replicates.
www.moleculartherapy.orgcould be mediated through (1) the proximal promoter element (2),
the enhancer element, and (3) the distance and interaction be-
tween transcription factor binding sites in the enhancer and the
proximal promoter. The more effective promoter element 454P
contains additional binding sites for the transcriptional regulators
TCF7L1 (regulator of Wnt signaling),41 MYC (highly pleiotropic
transcription factor),42 and POU5F1 (involved in embryonic
development and stem cell pluripotency;43 Figure 3A). Addition-
ally, in promoter variants containing 454P(hGRM6), the distance
between TF binding sites in the enhancer and the proximal pro-
moter is reduced, which was previously linked to enhanced
promoter functionality.15 The observed difference in terms of
cOBC preference between promoters 770En_454P(hGRM6) and
407En_454P(hGRM6) must lie in the enhancer element 770En.
The 50 region of 770En contains additional binding sites for
CTCF (transcriptional and epigenetic regulation),44 DACH1 (tran-
scriptional regulator implicated in neural development),45,46 and
FLI1 (activator, proto-oncogene),47 which may all be involved in
the enhancement of activity. Since FLI1 is known to homo-
dimerize with itself and hetero-dimerize with ERG,48 DNA looping
through binding with FLI1 and ERG contained in the proximal
promoter may approximate enhancer and promoter, which may
potentially enhance functionality in cOBCs. Indeed, a recent study
described a synergistic role of FLI1 and ERG in the gene regulation
of endothelial cells.49
Besides leveraging OBC-targeted clinical gene supplementation and
optogenetic gene therapies with the potential to restore high-acuityMolecular Therapy: Methodsvision, 770En_454P(hGRM6) also empowers
basic research, for the first time permitting
controlled manipulation of OBC activity across
species. This will contribute to ongoing revelationsof the still rather elusive inner retinal signaling, not only in health but,
importantly, also in degenerated retinal tissue. These insights can, in
turn, serve as an exemplar for other degenerating neuronal networks.
In summary, promoter 770En_454P(hGRM6) mediates highly OBC-
specific, robust, and durable transgene expression, even in the late de-
generated retina and possesses the unique ability to effectively drive
transgene expression in cOBCs resident in the human fovea and medi-
ating high-acuity vision.
MATERIALS AND METHODS
Bioinformatic Analysis and Promoter Design
We obtained genomic sequences and information on DNase I clus-
ters, H3K27Ac marks, and cross-species conservation for GRM6
and Grm6 from the Genome Browser of the Genomics Institute of
the University of California, Santa Cruz (https://genome.ucsc.edu/,
assemblies GRCh37/hg19, GRCh38/hg38, and GRCm38/
mm10).50,51We retrieved ChIP-seq data from the Gene Transcription
Regulation Database (http://gtrd.biouml.org/)19,20 and performed
sequence alignments online with “blastn” (https://blast.ncbi.nlm.
nih.gov/Blast.cgi).52,53
Quantitative Real-Time PCR of Grm6 Transcription
isolated RNA with the SV Total RNA Isolation System (Promega,
Z3100) from the pooled retinas of each mouse and performed quan-
titative real-time PCRs in duplicates with the Luna Universal One-
Step RT-qPCR Kit (New England Biolabs, E3005) using KiCqStart
SYBR Green Primers (KSPQ12012G) for Grm6, Rho, and the
reference gene Rpl8. We used Equation 3 to mitigate the& Clinical Development Vol. 17 June 2020 515
Molecular Therapy: Methods & Clinical Developmentunderestimation of Grm6 transcription levels in the early stages of
degeneration.
VaðGrm6; xÞ = VmðGrm6; xÞ


#rods VmðRho; xÞ
VmðRho; C57BL6JÞ + #ðother cellsÞ

;
(Equation 3)
where Va stands for value adjusted, Vm stands for value measured,
and x stands for the time point in degeneration; #rods represents
the average amount of rods (6.4 Mio),54 and #(other cells) represents
the average amount of non-rod cells (1.678 Mio)54,55 in a healthy
mouse retina. The adjustment is an estimate that assumes that the ef-
fect of changing non-rod cell numbers during degeneration is negli-
gible. We further normalized the adjusted and measured values to
the respective values of the wild-type animals.Promoter Cloning and Viral Vectors
We isolated human genomic DNA from blood with the Nucleo-
Spin Blood Kit (Macherey-Nagel, 740951). We PCR-amplified
GRM6 enhancer and proximal promoter sequences, combined
them into synthetic promoters, and then cloned the promoters
into AAV plasmids. For HRE experiments, we used the scAAV
plasmid pAAVsc_U7DTex2356 (a kind gift by P. Odermatt and
L. Garcia) as the backbone. To clone the synthetic promoters up-
stream of reporter mCitrine, followed by the woodchuck hepatitis
virus posttranscriptional regulatory element (WPRE) and the
short polyadenylation signal sNRP1-pA,57 we PCR-amplified
XbaI-NheI-MfeI-MfeI-AgeI-Kozak-mCitrine-WPRE-sNRP-1 pA-
MluI from plasmid pAAV-4xGRM6-SV40_Opto-mGluR6_
IRES_mCitrine_WPRE_BGH pA14 and inserted it into pAAVsc_
U7DTex23 using restriction sites XbaI and MluI. Into
this new backbone, we then inserted the synthetic promoters up-
stream of mCitrine by restriction with EcoRI/MfeI (compatible
cohesive ends) and AgeI for 407En_454P(hGRM6) and
407En_566P(hGRM6), or restriction with XbaI and AgeI for
770En_454P(hGRM6) (Figure S8). For mouse experiments, we
cloned the plasmid backbone pAAV-4xGRM6-SV40_Opto-
mGluR6_IRES_TruboFP635_WPRE_BGH pA as described by
van Wyk et al.14 but with TurboFP635 instead of mCitrine.
Then, we PCR-amplified Opn1mw from murine retinal cDNA
(GoScript Reverse Transcriptase, Promega), replacing the
stop codon with the entire C terminus of mGluR6 followed by
a Golgi export signal (TS)26 and the rhodopsin trafficking
sequence (TETSQVAPA, 1D4 epitope). We subsequently
replaced 4xGRM6-SV40_Opto-mGluR6 in the plasmid backbone
by using adaptor PCR and the In-Fusion HD Cloning
Plus Kit (Takara, 638909). We again used adaptor PCR to
then insert 770En_454P(hGRM6) upstream of Opn1mw,
resulting in ssAAV plasmid pAAV-770En_454P(hGRM6)-
Opn1mw-CTmGluR6-TS-1D4-IRES2-TurboFP635-WPRE-BGHpA
(Figure S5). We packaged viral vectors with capsids AAV2(7m8)21
andAAV2(Y252,272,444,500,700,730F)4,24 as described elsewhere.14
Vector NTI Advance was used for generating plasmid maps.516 Molecular Therapy: Methods & Clinical Development Vol. 17 June 2Mouse Injections
We obtained C57BL/6J and C3H/HeOuJ (rd1) mice from breeding
stocks at the Jackson Laboratory (Bar Harbor, ME, USA). Mice
were kept and bred under standard conditions and according to legal
requirements. The Swiss Veterinary Office reviewed and approved all
animal experiments and procedures. The same skilled person per-
formed all intravitreal injections as described elsewhere.14
HRE Cultures and Viral Transduction
All procedures were in accordance with the tenets of the Declaration
of Helsinki and complied with governmental regulations. No ethics
approval was required for this study as per national laws and regula-
tions (Federal Act on Research involving Human Beings [Human
Research Act, HRA 810.30, Art. 38]), and the Swiss Ethics Committee
reviewed this study and exempted it from the ethics review process.
The anonymized donor tissue was provided by the Department of
Ophthalmology, Inselspital, Bern University Hospital, Bern,
Switzerland. We prepared and handled HREs as previously
described.14 In short: we prepared HREs of approximately 50 mm2
from the mid-periphery (8–15 mm distal from the macula) of the
retina or from the macula 3–24 h post-mortem and cultured them
in R16 medium with supplements.58 To prevent the virus from flow-
ing into the culturing medium, we placed a small volume (3 mL) of
viral solution directly onto the ganglion cell side of the retina, in
the middle of the explant. We processed HREs for immunohisto-
chemistry after 7 days in culture.
Immunohistochemistry
We fixed mouse retinas, after enucleation and removal of the cornea
and lens, for 2 h and human retinas for 30 min in 4% paraformalde-
hyde (PFA) and subsequently cryo-protected them in a sucrose
gradient (10%, 20%, and 30% (wt/wt) sucrose in PBS) for a minimum
of 2 h at each concentration. For cryosectioning, we embedded retinas
with Tissue-Tek O.C.T. Compound (Sakura Finetek) in cryomolds,
froze them in liquid-nitrogen-cooled 2-methylbutane, cut them into
vertical cryo-sections of 15-mm thickness on a cryostat (Leica), and
mounted them on SuperFrost Ultra Plus Adhesion slides (Thermo
Scientific). We used 2xNGS (Sigma-Aldrich, G9023) and 2xNDS
(Sigma-Aldrich, D9663) (6% normal serum, 2% BSA, and 0.3%
Triton X-100 in 1 PBS) and prepared antibody solutions (AB solu-
tions) (Table S1) in 1 blocking solution (mixed 1:1 with 1 PBS).
After 1 h of blocking, we incubated slides in primary AB solution
overnight at 4C and subsequently in secondary AB solution with
DAPI (0.65 mg/mL, Sigma-Aldrich) for 2 h at room temperature.
For the triple staining with anti-Gao, we used a sequential staining
protocol: We first stained against PKCa and mCitrine as described
earlier and then incubated the sections with anti-Gao for 2 h at
room temperature and subsequently with anti-Mouse Cyanine 5 for
another 2 h at room temperature. For staining of whole mounts or
flat mounts, we blocked samples in blocking solution overnight and
incubated in primary AB solution for 6 days at 4C and in secondary
AB solution for 5 days at 4C. Finally wemounted the stained samples
on glass slides with Fluoromount mounting medium (Sigma-Aldrich,
F4680).020
www.moleculartherapy.orgMicroscopy and Quantitative Fluorescence Measurements
We used a ZEISS LSM 880 with Airyscan and ZEN 2.1 software and
either a Plan-Apochromat 20/0.8 M27 or a Plan-Apochromat 40/
1.3 Oil DIC M27 objective lens and performed image processing and
evaluation in Fiji. We measured FVs in different areas of immunola-
beled cryo-sections by selecting cell bodies with the freehand selection
tool of Fiji and measuring the average FV of Alexa 488-labeled
mCitrine with the “analyze-measure” command. We treated samples
as identically as possible but normalized the median of measured FVs
to the background fluorescence in untransduced OBCs to compensate
for remaining experimental variations. For better comparison, we also
normalized the fluorescence intensities measured in the triple-stained
sections to the intensities measured in the double-stained sections.
The total number of cells measured for FVs or counted for cell-type
specificity quantification is given in Table S2.
Optomotor Reflex Measurements
We measured visual acuity by OMRs in the OptoDrum (Striatech)
virtual optomotor system. It contained a small chamber (54  54 
30 cm) with four screens (23.8”, 1920x1080 pixel resolution, in-plane
switching [IPS] screen) surrounding a platform. The brightness of the
screens was adjusted to 1013 photons cm2 s1, and the bottom and
the top of the chamber were covered with mirrors. Head movements
of unrestrained mice sitting on an elevated platform (9-cm diameter,
10-cm height) were tracked from above by an infrared-sensitive dig-
ital camera (1/3” complementary metal oxide semiconductor
(CMOS) sensor with global shutter and wide-angle lens, F1.6) while
a rotating pattern of black and white vertical bars was displayed at
different spatial frequencies controlled by the software. The velocity
of the moving bars was set to 12/s, and the contrast was set to
100%. Optodrum software analyzed the recorded head movements,
evaluated whether the mice followed the stimulus pattern, and rated
the trial as positive or negative. Visual acuity of optogenetically
treated rd1 mice at different time points in degeneration were not
significantly different (ANOVA, p = 0.214; CI95% of difference for
weeks 33–28 = [0.091, 0.209]; CI95% of difference for weeks 38–
28 = [0.2, 0.1]; CI95% of difference for weeks 38–33 [0.293,
0.074]; Figure S6); therefore, we used the averages of the trials of in-
dividual mice for comparisons with positive and negative controls.
Statistics
We performed statistical tests in R v.3.6.0.59 We used one-way
ANOVA for multiple comparisons with post hoc analysis with Tu-
key’s honestly significant difference (HSD). We used Welch’s t test
for comparisons between two populations. Assumptions of normality
were not rejected by the Shapiro-Wilk normality test, and assump-
tions of homoscedasticity were not rejected by Levene’s test for homo-
geneity of variance. In graphs, the significance levels are indicated as p
% 0.05, p % 0.01, and p % 0.001. Values are given as the mean ±
standard deviation of biological replicates.
We performed power calculations with the pwr.anova.test function to
estimate the required sample size for all experiments comparing syn-
thetic promoter variants and the different treatment groups in opto-Moleculmotor reflex measurements. We estimated standard deviations (SDs)
through pilot experiments (HRE experiments) or with values re-
ported in the literature28 (OMR): SD for cOBC preference, 4.8%;
SD for normalized fluorescence, 1.09; and SD for visual acuity, 0.04
cpd. We anticipated the following differences between group means
to be scientifically meaningful and functionally relevant: cOBC
preference, 10%; normalized fluorescence, 2.4 (50% of the mean
of the pilot experiment); and visual acuity, 0.1 cpd. Dividing these
in-between group mean differences by the respective SDs, we calcu-
lated the following effect sizes; cOBC preference, 2.083; normalized
fluorescence, 2.213; and visual acuity, 2.5. We performed power
calculations for an ANOVA of 3 groups (for the three synthetic
promoters 407En_454P(hGRM6), 407En_566P(hGRM6), and
770En_454P(hGRM6) or 3 groups of mice in the OMR experiments)
at a significance level of 0.05 and power of 0.9, which all yielded neces-
sary biological sample sizes of between 2 and 3.
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